食管癌根治性同步放化疗

doi:10.3760/cma.j.issn.1673-422X.2016.01.014

摘要/Abstract

摘要： 美国国家综合癌症网络指南指出，对于ⅠB～ⅢA期食管癌患者可行根治性PF方案（顺铂+5氟尿嘧啶）同步放化疗。国内外一些学者对PF方案及放疗剂量作了进一步优化研究，提高了局部控制率和生存率，不良反应在可控范围内。近年来一些新药如卡培他滨、紫杉醇、多西他赛、培美曲塞、卡铂等在根治性同步放化疗中也显示出其优势。

关键词: 食管肿瘤, 放射疗法, 药物疗法, 卡培他滨

Abstract: In National Comprehensive Cancer Network guideline, patients with the clinical stages of ⅠBⅢA esophageal neoplasms should be given radical PF regimen (cisplatin + 5fluorouracil) concurrent chemoradiotherapy. The majorization PF and radiation dosage are studied by some scholars in China and abroad, and the local control rate and survival rate are improved, adverse reaction is within a controllable range. In recent years, some new drugs such as capecitabine, paclitaxel, docetaxel, pemetrexed and carboplatin also show their advantages in radical concurrent chemoradiotherapy.

Key words: Esophageal neoplasms, Radiotherapy, Drug therapy, Capecitabine

刘永萱, 冯笑山. 食管癌根治性同步放化疗[J]. 国际肿瘤学杂志, 2016, 43(1): 49-52.

Liu Yongxuan, Feng Xiaoshan. Radical concurrent chemoradiotherapy for esophageal carcinoma[J]. Journal of International Oncology, 2016, 43(1): 49-52.

参考文献

［1］ Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012［J］. CA Cancer J Clin, 2015, 65(2): 87-108. DOI:10.3322/caac.21262. ［2］董颖, 杨文君. 消化道恶性肿瘤流行病学特征与发病现状分析［J］. 医学综述, 2014, 20(3): 429-431. DOI:10.3969/j.issn.1006-2084.2014.03.015. ［3］ Siegel R, Naishadham D, Jemal A. Cancer Statistics, 2013［J］. CA Cancer J Clin, 2013, 63(1): 11-30. DOI:10.3322/caac.21166. ［4］ Rackley T, Leong T, Foo M, et al. Definitive chemoradiotherapy for oesophageal cancera promising start on an exciting journey［J］. Clin Oncol (R Coll Radiol), 2014, 26(9): 533-540. DOI:10.1016/j.clon.2014.06.001. ［5］ Chen W, Zheng R, Zhang S, et al. Report of cancer incidence and mortality in China, 2010［J］. Ann Transl Med, 2014, 2(7): 61. DOI:10.3978/j.issn.2305-5839.2014.04.05. ［6］ Tong DK, Law S, Kwong DL, et al. Current management of cervical esophageal cancer［J］. World J Surg, 2011, 35(3): 600-607. DOI:10.1007/s00268-010-0876-7. ［7］ Welsh J, Settle SH, Amini A, et al. Failure patterns in patients with esophageal cancer treated with definitive chemoradiation［J］. Cancer, 2012, 118(10): 26322640. DOI:10.1002/cncr.26586. ［8］ Blum MA, Taketa T, Sudo K, et al. Chemoradiation for esophageal cancer［J］. Thorac Surg Clin, 2013, 23(4): 551-558. ［9］ Conroy T, Galais MP, Raoul JL, et al. Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial［J］. Lancet Oncol, 2014, 15(3): 305-314. ［10］ Tougeron D, Richer JP, Silvain C. Management of esophageal adenocarcinoma［J］. J Visc Surg, 2011, 148(3): e161-170. DOI:10.1016/j.jviscsurg.2011.05.008. ［11］ Akutsu Y, Matsubara H. The significance of lymph node status as a prognostic factor for esophageal cancer［J］. Surg Today, 2011, 41(9): 11901195. DOI:10.1007/s00595-011-4542-y. ［12］ Kato K, Muro K, Minashi K, et al. Phase Ⅱ study of chemoradiotherapy with 5fluorouracil and cisplatin for stage Ⅱ-Ⅲ esophageal squamous cell carcinoma: JCOG Trial (JCOG 9906)［J］. Int J Radiat Oncol Biol Phys, 2011, 81(3): 684690. DOI:10.1016/j.ijrobp.2010.06.033. ［13］ Kato K, Nakajima TE, Ito Y, et al. Phase Ⅱ study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for stage Ⅱ-Ⅲ esophageal carcinoma［J］. Jpn J Clin Oncol, 2013, 43(6): 608-615. DOI:10.1093/jjco/hyt048. ［14］ Yamashita H, Omori M, Takenaka R, et al. Involvedfield irradiation concurrently combined with nedaplatin/5fluorouracil for inoperable esophageal cancer on basis of (18)FDGPET scans: a phase Ⅱ study［J］. Radiother Oncol, 2014, 113(2): 182-187. DOI:10.1016/j.radonc.2014.11.004. ［15］ Lee SJ, Ahn BM, Kim JG, et al. Definitive chemoradiotherapy with capecitabine and cisplatin in patients with esophageal cancer: a pilot study［J］. J Korean Med Sci, 2009, 24(1): 120125. DOI:10.3346/jkms.2009.24.1.120. ［16］ Xing L, Liang Y, Zhang J, et al. Definitive chemoradiotherapy with capecitabine and cisplatin for elder patients with locally advanced squamous cell esophageal cancer［J］. J Cancer Res Clin Oncol, 2014, 140(5): 867-872. DOI:10.1007/s00432-014-1615-5. ［17］尹雪, 刘杰, 田金徽. 紫杉醇联合顺铂同步放化疗治疗中晚期食管癌的Meta分析［J］. 肿瘤防治研究, 2012, 39(7): 851-854. DOI:10.3971/j.issn.10008578.2012.07.022. ［18］ Li QQ, Liu MZ, Hu YH, et al. Definitive concomitant chemoradiotherapy with docetaxel and cisplatin in squamous esopheageal carcinoma［J］. Dis Esophagus, 2010, 23(3): 253-259. DOI:10.1111/j.14422050.2009.01003.x. ［19］ Tang HR, Ma HF, An SM, et al. A phase Ⅱ study of concurrent chemoradiotherapy with paclitaxel and cisplatin for inoperable esophageal squamous cell carcinoma［J］. Am J Clin Oncol, 2014, In press. ［20］ Zhao T, Chen H, Zhang T. Docetaxel and cisplatin concurrent with radiotherapy versus 5fluorouracil and cisplatin concurrent with radiotherapy in treatment for locally advanced oesophageal squamous cell carcinoma: a randomized clinical study［J］. Med Oncol, 2012, 29(5): 3017-3023. DOI:10.1007/s12032-012-0228-6. ［21］ Higuchi K, Komori S, Tanabe S, et al. Definitive chemoradiation therapy with docetaxel, cisplatin, and 5fluorouracil (DCFR) in advanced esophageal cancer: a phase 2 trial (KDOG 0501P2)［J］. Int J Radiat Oncol Biol Phys, 2014, 89(4): 872-879. DOI:10.1016/j.ijrobp.2014.03.030. ［22］ Li BS, Gong HY, Huang W, et al. Phase Ⅰ study of concurrent selective lymph node late course accelerated hyperfractionated radiotherapy and pemetrexed, cisplatin for locally advanced esophageal squamous cell carcinoma［J］. Dis Esophagus, 2011, 24(4): 251257. DOI:10.1111/j.14422050.2010.01130.x. ［23］ Honing J, Smit JK, Muijs CT, et al. A comparison of carboplatin and paclitaxel with cisplatinum and 5-fluorouracil in definitive chemoradiation in esophageal cancer patients［J］. Ann Oncol, 2014, 25(3): 638-643. DOI:10.1093/annonc/mdt589. ［24］ Shen ZT, Wu XH, Li B, et al. Nedaplatin concurrent with threedimensional conformal radiotherapy for treatment of locally advanced esophageal carcinoma［J］. World J Gastroenterol, 2013, 19(48): 9447-9452. DOI:10.3748/wjg.v19.i48.9447. ［25］张发恩, 韦嵩, 韦春琳, 等. 三维适形放疗联合奥沙利铂加卡培他滨同步化疗治疗食管癌的疗效分析［J］. 实用癌症杂志, 2014, 29(2): 174-176. DOI:10.3969/j.issn.1001-5930.2014.02.019. ［26］ Chang H, Shin SK, Cho BC, et al. A prospective phase Ⅱ trial of S1 and cisplatinbased chemoradiotherapy for locoregionally advanced esophageal cancer［J］. Cancer Chemother Pharmacol, 2014, 73(4): 665-671. DOI:10.1007/s00280-013-2371-y.

[1]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[2]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[3]	刘静, 刘芹, 黄梅. 基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[4]	万芳, 杨钢, 李睿, 万启晶. 食管癌患者血清miR-497、miR-383水平及临床意义[J]. 国际肿瘤学杂志, 2024, 51(4): 204-209.
[5]	李书月, 马辰莺, 周菊英, 徐晓婷, 秦颂兵. 寡转移非小细胞肺癌的放疗进展[J]. 国际肿瘤学杂志, 2024, 51(3): 170-174.
[6]	李济时, 陆钊群, 刘俊茹, 吕建勋, 陈霜, 沈琳, 徐志渊, 吴平安. 新辅助放疗联合部分喉切除术治疗喉滑膜肉瘤1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(2): 123-125.
[7]	金旭东, 陈忠坚, 毛伟敏. MTAP基因在恶性间皮瘤中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(2): 99-104.
[8]	中国医师协会放射肿瘤治疗医师分会, 中华医学会放射肿瘤治疗学分会, 中国抗癌协会肿瘤放射治疗专业委员会. 中国食管癌放射治疗指南（2023年版）[J]. 国际肿瘤学杂志, 2024, 51(1): 1-20.
[9]	高新雨, 李振江, 孙洪福, 韩丹, 赵倩, 刘成新, 黄伟. 基于MR加速器的MR引导放疗在食管癌患者中的临床应用[J]. 国际肿瘤学杂志, 2024, 51(1): 37-42.
[10]	崔腾璐, 吕璐, 孙鹏飞. 放疗联合免疫治疗在头颈部鳞状细胞癌治疗中的应用[J]. 国际肿瘤学杂志, 2023, 50(9): 548-552.
[11]	山东省医学会肺癌食管癌多学科联合委员会. 山东省医学会食管癌多学科规范化诊疗指南（2023年版）[J]. 国际肿瘤学杂志, 2023, 50(7): 385-397.
[12]	李晨曦, 赵宏伟. 二次肿瘤细胞减灭术治疗初始减瘤手术不满意铂敏感复发性卵巢癌的预后及影响因素分析[J]. 国际肿瘤学杂志, 2023, 50(6): 342-347.
[13]	李青珊, 谢鑫, 张楠, 刘帅. 放疗联合系统治疗在乳腺癌中的应用进展[J]. 国际肿瘤学杂志, 2023, 50(6): 362-367.
[14]	许萌, 姜伟, 朱海涛, 曹雄锋. 癌相关成纤维细胞在肿瘤放疗抵抗中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(4): 227-230.
[15]	石小琪, 汪红艳. 肠道菌群与放射性肠炎的相互作用及研究进展[J]. 国际肿瘤学杂志, 2023, 50(4): 244-247.